Sobi® and Apellis Pharmaceuticals today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli® (pegcetacoplan) for the treatment of C3 ...
GOTHENBURG, SWEDEN / ACCESS Newswire / February 20, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, 20 ...
Biliary tract cancer is increasing in incidence and mortality across Europe, with more people under the age of 60 years old ...
The EUR/USD pair recovers some lost ground to near 1.0425 during the early European trading hours on Thursday. The weakening ...
Researchers have suggested that uniform evidence standards and reporting requirements could help speed patient access to cell and gene therapies and help ensure consistent safety and efficacy ...
Apellis and Sobi have global co-development rights for systemic pegcetacoplan. Sobi has exclusive ex-U.S. commercialization rights for systemic pegcetacoplan, and Apellis has exclusive U.S.
Apellis (APLS) and Sobi announced the European Medicines Agency has validated an indication extension application for Aspaveli for the ...
Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively ...
EUR/USD edges slightly higher as the US Dollar declines, with investors seeming less fearful about President Trump’s tariff ...
Foster City, California Thursday, February 20, 2025, 12:00 Hrs [IST] ...
The global Apheresis Equipment Market is valued at $2.01 million in 2023 and is projected to reach a value of $2.20 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback